Neurology

Carbidopa and levodopa extended-release capsules are a novel, oral formulation that combine immediate-release granules and extended-release pellets.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

Small adjustments in human pluripotent stem cell cultures and the molecule concentration patterns in the initial 5 days of differentiation are essential to “rescue” the lines.

Periodontitis and AD are both characterized by inflammatory and immunological response by the host.

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.

The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.

Understanding and accounting for linguistic diversity is critical in diagnostics and treatment for dementia.

Joshua Hare describes how Lomecel-B addresses neuroinflammation, unlike other treatments which typically target amyloid disposition.

The study also found that there were no associations with increased dementia risk when anxiety resolved.

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

The FDA’s designation builds off positive results in a phase 1b/2a clinical trial, showing that the vaccine can effectively target the Tau protein.

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

Acetylcholine deficit observed in patients with anorexia nervosa suggest potential targeted treatment options.

Jacqueline Bainbridge from the University of Colorado discussed what it meant to one of the recipients of the 2024 Giants of MS awards.

According to the authors, this vulnerability may stem from either sporadic occurrences of intergenerational chains of childhood abuse.

Multiple sclerosis is a debilitating disease affecting many Americans. Pharmacists can help patients control the symptoms that impact their quality of life.

After being previously approved in June 2023 under an Accelerated Approval process, the FDA has granted an expanded approval for non-ambulatory individuals and individuals 4 years of age or older.

Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.

Eating a poor diet might lead to structural brain changes that cause the development of common mental disorders (CMD).

The default-mode network method, which was analyzed using functional magnetic resonance imaging scans, was approximately 80% accurate when predicting dementia up to 9 years prior to a diagnosis.

Donanemab was able to significantly slow clinical progression of Alzheimer disease and amyloid and tau pathology at 76 weeks of treatment.

The authors noted that these networks have a significant role in intellectual ability, physical coordination, working memory, emotional processing, and overall mental health.

The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.

In addition to racial inequities in access to care, socioeconomic challenges are very common for the specialty medications necessary in MS.

Understanding patients’ specific experiences and challenges is crucial to helping them improve medication adherence.